|
|
News Breaks
|
November 2, 2009
|
| 09:03 EDT |  | ENZ |
| theflyonthewall.com: | Enzo Biochem announces favorable EGS21 clinical trial results | | Enzo Biochem announced that favorable results of the company’s clinical trial for treatment of non-alcoholic steatohepatitis, or NASH, were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome. Enzo scientists and collaborators presented data showing that “oral administration of EGS21 appears to be safe and biologically active in patients with insulin resistance and NASH, leading to decreased hepatic steatosis, and improved insulin resistance.” :theflyonthewall.com |
|
|
News For ENZ From The Last 14 Days Check below for free stories on ENZ the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
